Comparison of subcutaneous interferon beta-1a with glatiramer acetate in patients with relapsing multiple sclerosis (the REbif vs Glatiramer Acetate in Relapsing MS Disease [REGARD] study): a multicentre, randomised, parallel, open-label trial
Top Cited Papers
- 10 September 2008
- journal article
- research article
- Published by Elsevier in The Lancet Neurology
- Vol. 7 (10), 903-914
- https://doi.org/10.1016/s1474-4422(08)70200-x
Abstract
No abstract availableKeywords
This publication has 28 references indexed in Scilit:
- Ethics of placebo-controlled clinical trials in multiple sclerosisNeurology, 2008
- The Immunopathology of Multiple Sclerosis: An OverviewBrain Pathology, 2007
- A Randomized, Placebo-Controlled Trial of Natalizumab for Relapsing Multiple SclerosisNew England Journal of Medicine, 2006
- Acute Delirium, Delusion, and Depression During IFN-β-1a Therapy for Multiple Sclerosis: A Case ReportClinical Neuropharmacology, 2003
- European/Canadian multicenter, double‐blind, randomized, placebo‐controlled study of the effects of glatiramer acetate on magnetic resonance imaging–measured disease activity and burden in patients with relapsing multiple sclerosisAnnals of Neurology, 2001
- Defining the clinical course of multiple sclerosisNeurology, 1996
- Intramuscular interferon beta‐1a for disease progression in relapsing multiple sclerosisAnnals of Neurology, 1996
- Copolymer 1 reduces relapse rate and improves disability in relapsing‐remitting multiple sclerosisNeurology, 1995
- Rating neurologic impairment in multiple sclerosisNeurology, 1983
- New diagnostic criteria for multiple sclerosis: Guidelines for research protocolsAnnals of Neurology, 1983